Donald Trump's pick for the Department of Health and Human Services has sent healthcare stocks tumbling. The consequences are also being felt on the Swiss stock exchange. 

Wall Street closed at a new all-time high following Donald Trump's election victory. However, not all sectors benefit from the president-elect's likely economic agenda. 

Investors have yet to digest US pharmaceutical giant Eli Lilly's disappointing quarterly results. Shares remain under pressure after its appetite suppressants failed to meet high sales expectations. However, demand for the drugs appears to remain strong.

In about a week, Americans will elect their next president. This will mark the end of an emotional and turbulent election campaign. However, investors would be well advised to keep a cool head and make their investment decisions independently of political considerations. The ZKB Capital Protection Certificate allows you to participate fully in the S&P 500 Index, provided that the knock-out level of 120% is not reached.

The Chinese government is increasing its efforts to tackle the country's economic slowdown. However, initial enthusiasm in financial markets has faded. For investors, the situation opens up investment opportunities.

US technology stocks are approaching their July highs. Yield enhancement products with a quanto feature allow investors to benefit from yield opportunities while hedging the currency risk.

Givaudan continues to thrive, benefiting from its strong fine fragrances business. This development is also reflected in the share price of the company. However, not all chemical manufacturers are equally successful, as a look at Sika and Clariant shows.

Expectations are high for the US tech giants' quarterly results. However, the stock market's enthusiasm for artificial intelligence has cooled in recent months.

The Swiss equity market performed quite well in the first three quarters of the year. Now, financial markets are heading for an eventful final quarter.